Instead of developing something that offers little, if any, improvement over a first-in-class drug -- say, yet another high-cholesterol treatment -- critics have contended that drug makers should use precious R&D resources to focus on developing therapies for ailments that are lacking treatments.
Now, though, a new analysis suggests the me-too phenomenon often occurred because companies were simply engaging in concurrent drug development, rather than opportunistic efforts to ride on the coattails of a successful medicine.
Read Full Article »